Pharm-Olam International Adds Executive Director, Strategic Projects to Its Global Strategic Operations Team
Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is pleased to welcome Tricia A. Bland to its management team as the Executive Director, Strategic Projects.
Ms. Bland brings over 20 years of demonstrated success in the clinical research industry, leading and implementing global development strategies and successfully managing global teams. She will be based out of Pharm-Olam’s Research Triangle Park, North Carolina office. Ms. Bland will provide executive-level leadership to both staff and sponsors, strategic relationship management, and implementation of process improvement programs aimed at increasing efficiencies and improving data quality. Prior to coming to Pharm-Olam, Ms. Bland held management roles including Vice President of Corporate Development and Vice President of Proposals and Contracts at several CROs.
“We are thrilled to have Tricia join the Pharm-Olam team,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). Suri added, “We continually look for ways to assist pharmaceutical, biotechnology, and device companies with innovative clinical trial solutions around the world. We know how important our team members are to study success and Tricia’s addition to our team will enable us to offer distinctive ideas to support our client’s unique needs.”
For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact email@example.com .
About Pharm-Olam International Group
Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com .
Mark Eberhardt, 713-559-7350
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NJ-WIPRO-LIMITED21.6.2018 15:24 | pressemeddelelse
Wipro Positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide
SEOUL-SEMICONDUCTOR21.6.2018 15:02 | pressemeddelelse
Seoul Semiconductor Captures the Home Lighting Market with Its Innovative LED SunLike Technology
ANT-FINANCIAL-SERVICES21.6.2018 14:58 | pressemeddelelse
MYbank Launches Star Plan to Support 1,000 Financial Institutions to Serve 30 Million SMEs in the Next Three Years
IFA21.6.2018 14:30 | pressemeddelelse
IFA 2018 : LG CEO and CTO to Outline Ambitious Strategy for ThinQ AI at IFA Opening Keynote
SERVIER21.6.2018 13:12 | pressemeddelelse
Servier and Taiho Announce Phase III Trial Data Demonstrates Significant Overall Survival Benefit of LONSURF® (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
SIMSCALE21.6.2018 12:51 | pressemeddelelse
SimScale Announces a Preview Program of FDS for Simulation of Fire Scenarios in Buildings
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum